Canaccord Genuity analyst William Plovanic maintained a Buy rating on Nevro Crop (NYSE:NVRO) on Monday, setting a price target of $167, which is approximately 1.27% below the present share price of $169.15.
Plovanic expects Nevro Crop to post earnings per share (EPS) of -$0.29 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Nevro Crop, with an average price target of $196.29.
The analysts price targets range from a high of $215 to a low of $167.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $108.46 million and a net profit of -$3.55 million. The company's market cap is $5.82 billion.
According to TipRanks.com, Canaccord Genuity analyst William Plovanic is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.5% and a 53.15% success rate.
Nevro Corp . engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood (NYSE:RWT) City, CA.